Syndax Revenue Per Share from 2010 to 2024

SNDX Stock  USD 13.93  0.46  3.41%   
Syndax Pharmaceuticals Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share is likely to outpace its year average in 2024. Revenue Per Share is the amount of revenue generated by Syndax Pharmaceuticals per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
2.42
Current Value
2.54
Quarterly Volatility
1.16063811
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Syndax Pharmaceuticals over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Syndax Pharmaceuticals' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.19510 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Syndax Revenue Per Share Regression Statistics

Arithmetic Mean0.72
Geometric Mean0.13
Coefficient Of Variation160.11
Mean Deviation0.99
Median0.05
Standard Deviation1.16
Sample Variance1.35
Range2.6473
R-Value0.77
Mean Square Error0.60
R-Squared0.59
Significance0.0009
Slope0.20
Total Sum of Squares18.86

Syndax Revenue Per Share History

2024 2.54
2023 2.42
2021 2.68
2020 0.0367
2019 0.0498
2018 0.0598
2017 0.1

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 2.42  2.54 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.